Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome

Gynecol Endocrinol. 2020 Sep;36(9):760-763. doi: 10.1080/09513590.2020.1739267. Epub 2020 Mar 11.

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder that affects women in reproductive age. This study aimed to evaluate Gal-3 levels and its role on metabolic parameters in women with PCOS. Gal-3 was measured in 44 PCOS and 25 women recruited as control group for the case-control study. Gal-3 levels were similar between PCOS and control groups (p > 0.05), but showed a positive correlation with glucose levels in the oral glucose tolerance test (OGTT) (r = 0.403, p = 0.037), body mass index (BMI) (r = 0.469, p = 0.027), insulin levels (r = 0.453, p = 0.030) and HOMA-IR (r = 0.738, p = 0.037) in PCOS group. The data suggest that Gal-3 plays a role in the pathophysiology of the insulin resistance and obesity in PCOS group.

Keywords: Polycystic ovary syndrome; galectin-3; glucose; insulin resistance; obesity.

MeSH terms

  • Adult
  • Biomarkers / blood*
  • Blood Proteins
  • Body Mass Index
  • Case-Control Studies
  • Female
  • Galectins / blood*
  • Glucose Tolerance Test
  • Humans
  • Insulin Resistance / physiology*
  • Obesity / blood*
  • Obesity / complications
  • Obesity / diagnosis
  • Polycystic Ovary Syndrome / blood*
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / diagnosis

Substances

  • Biomarkers
  • Blood Proteins
  • Galectins
  • LGALS3 protein, human